At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 485 enrolled
Drug / intervention
Bimatoprost +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy and Safety Assessment of T4032 Versus Lumigan® in Ocular Hypertensive or Glaucomatous Patients
In Brief
A Phase 3 clinical trial evaluating Bimatoprost and Lumigan® for Ocular Hypertension and Glaucoma. Completed, enrolled 485 participants across 1 site.
Detailed Summary
The purpose of this study is to assess the efficacy and safety of T4032 versus Lumigan.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOcular Hypertension, Glaucoma
CountriesEstonia
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
Enrollment StartNov 2018
First PostedJan 2019
Primary CompletionFeb 2021
Study CompletionFeb 2021
TodayJul 2026
First PostedJan 31, 2019
Enrollment StartNov 23, 2018
Primary CompletionFeb 3, 2021
Study CompletionFeb 24, 2021
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 7.4 years ago
Interventions
Bimatoprostdrug
Eyedrops
Lumigan®drug
Eyedrops